Cellectis (NASDAQ: CLLS) reported Q3 EPS of ($0.58), $0.16 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $1.88 million versus the consensus estimate of $3.58 million.

For earnings history and earnings-related data on Cellectis (CLLS) click here.